FDA Labels Germ DNA Stabilizer Device as Class II
Published Date: 5/6/2026
Rule
Summary
The FDA is officially putting a special label (Class II) on devices that keep tiny germs’ DNA stable in medical samples. This change makes sure these devices are safe and work well, while also making it easier and faster for new, helpful devices to reach patients. The new rules started May 6, 2026, and could save time and money for companies making these devices.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Device Reclassified to Class II
The FDA officially classed devices that preserve and stabilize microbial nucleic acids as Class II (special controls) effective May 6, 2026; the classification was applicable on November 3, 2021. Because this was done through the De Novo process, this device type can serve as a predicate for future devices so other sponsors may use the less-burdensome 510(k) pathway instead of a De Novo request or premarket approval.
Easier Patient Access to Microbiome Tests
The FDA says this Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. That means patients may see new devices for stabilizing microbial nucleic acids reach clinical use more quickly after May 6, 2026.
510(k) Premarket Notification Requirement
Devices of this type are subject to premarket notification under section 510(k) of the FD&C Act unless and until FDA exempts them. Sponsors must therefore prepare and submit a 510(k) to market these Class II devices.
New Special Controls: Labeling and Studies
The rule sets special controls requiring specific labeling and validation studies: labels must list specimen types, device description, a warning that the device is not for detecting specific pathogens, and a warning to use only with legally marketed assays. Sponsors must also provide detailed design verification and validation documentation, including microorganism panels, extraction platforms, assay protocols, bioinformatic pipelines, and usability studies for collection when applicable.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in